{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:05:38Z","timestamp":1790737538224,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry Global Open Science"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bpsgos.2026.100725","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:50:58Z","timestamp":1774659058000},"page":"100725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a Study"],"prefix":"10.1016","volume":"6","author":[{"given":"James A.","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3417-8977","authenticated-orcid":false,"given":"Mark E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mazzucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn F.","family":"Ionescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1124-3484","authenticated-orcid":false,"given":"Silke","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqin S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne C.","family":"Drevets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpsgos.2026.100725_bib1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41380-018-0044-2","article-title":"Pharmacological treatment of adult bipolar disorder","volume":"24","author":"Baldessarini","year":"2019","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100725_bib2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S2215-0366(24)00411-5","article-title":"Real-world effectiveness of pharmacological maintenance treatment of bipolar depression: A within-subject analysis in a Swedish nationwide cohort","volume":"12","author":"Ermis","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100725_bib3","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.biopsych.2008.11.029","article-title":"Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression","volume":"65","author":"Miller","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100725_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri.2015.5","article-title":"The role of inflammation in depression: From evolutionary imperative to modern treatment target","volume":"16","author":"Miller","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bpsgos.2026.100725_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.mcn.2012.10.002","article-title":"The role of the innate immune system in psychiatric disorders","volume":"53","author":"Jones","year":"2013","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.bpsgos.2026.100725_bib6","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/mp.2009.47","article-title":"Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients","volume":"15","author":"Rao","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100725_bib7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1503\/jpn.100080","article-title":"Elevation of cerebrospinal fluid interleukin-1\u03b2 in bipolar disorder","volume":"36","author":"S\u00f6derlund","year":"2011","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.bpsgos.2026.100725_bib8","first-page":"664","article-title":"Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression","volume":"10","author":"Koo","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.bpsgos.2026.100725_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12974-020-01848-8","article-title":"NLRP1 inflammasome contributes to chronic stress-induced depressive-like behaviors in mice","volume":"17","author":"Song","year":"2020","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.bpsgos.2026.100725_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-444-63380-4.00002-0","article-title":"P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders","volume":"53","author":"Chrovian","year":"2014","journal-title":"Prog Med Chem"},{"key":"10.1016\/j.bpsgos.2026.100725_bib11","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1074\/jbc.M010353200","article-title":"A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor","volume":"276","author":"Gu","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bpsgos.2026.100725_bib12","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1096\/fj.09-150862","article-title":"Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1beta secretion","volume":"24","author":"Stokes","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.bpsgos.2026.100725_bib13","doi-asserted-by":"crossref","first-page":"17108","DOI":"10.1074\/jbc.M212759200","article-title":"An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor","volume":"278","author":"Wiley","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bpsgos.2026.100725_bib14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2125.2012.04200.x","article-title":"Effects of genetic variation in the P2RX7 gene on pharmacodynamics of a P2X(7) receptor antagonist: A prospective genotyping approach","volume":"74","author":"McHugh","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bpsgos.2026.100725_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbr.2008.10.018","article-title":"Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: Relevance for neuropsychiatric disorders","volume":"198","author":"Basso","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bpsgos.2026.100725_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066547","article-title":"Neurochemical changes in the mouse hippocampus underlying the antidepressant effect of genetic deletion of P2X7 receptors","volume":"8","author":"Cs\u00f6lle","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bpsgos.2026.100725_bib17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s12035-014-9031-z","article-title":"Role of P2X7 receptor in an animal model of mania induced by D-amphetamine","volume":"53","author":"Gubert","year":"2016","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.bpsgos.2026.100725_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.biopsych.2015.11.026","article-title":"Psychological stress activates the inflammasome via release of adenosine triphosphate and stimulation of the purinergic Type 2X7 receptor","volume":"80","author":"Iwata","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100725_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1021\/cn500054n","article-title":"The first CNS-active carborane: A novel P2X7 receptor antagonist with antidepressant activity","volume":"5","author":"Wilkinson","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bpsgos.2026.100725_bib20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12974-017-0865-y","article-title":"Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors","volume":"14","author":"Yue","year":"2017","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.bpsgos.2026.100725_bib21","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41386-018-0141-6","article-title":"Neuropsychopharmacology of JNJ-55308942: Evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia","volume":"43","author":"Bhattacharya","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bpsgos.2026.100725_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fphar.2018.00030","article-title":"Recent advances in CNS P2X7 physiology and pharmacology: Focus on neuropsychiatric disorders","volume":"9","author":"Bhattacharya","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bpsgos.2026.100725_bib23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/cts.12711","article-title":"Translational model-informed dose selection for a human positron emission tomography imaging study of JNJ-54175446, a P2X7 receptor antagonist","volume":"13","author":"Xu","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.bpsgos.2026.100725_bib24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","article-title":"A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression","volume":"162","author":"Calabrese","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100725_bib25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1185\/030079908X291958","article-title":"The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach","volume":"24","author":"Duru","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bpsgos.2026.100725_bib26","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","article-title":"Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: A Phase 3 randomized placebo-controlled trial","volume":"178","author":"Calabrese","year":"2021","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100725_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pnpbp.2019.01.006","article-title":"Association of purinergic receptor P2RX7 gene polymorphisms with depression symptoms","volume":"92","author":"Vereczkei","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100725_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.64719\/pb.4412","article-title":"Consistently modest antidepressant effects in clinical trials: The role of regulatory requirements","volume":"51","author":"Khan","year":"2021","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.bpsgos.2026.100725_bib29","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/mds.30307","article-title":"Anti-neuroinflammatory and anti-inflammatory effects of the NLRP3 inhibitor NT-0796 in subjects with Parkinson\u2019s disease","volume":"40","author":"Clarke","year":"2025","journal-title":"Mov Disord"},{"key":"10.1016\/j.bpsgos.2026.100725_bib30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jad.2016.11.021","article-title":"The difficult lives of individuals with bipolar disorder: A review of functional outcomes and their implications for treatment","volume":"209","author":"Gitlin","year":"2017","journal-title":"J Affect Disord"},{"key":"10.1016\/j.bpsgos.2026.100725_bib31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jad.2016.03.028","article-title":"Coping strategies and real-world functioning in bipolar disorder","volume":"198","author":"Nitzburg","year":"2016","journal-title":"J Affect Disord"},{"key":"10.1016\/j.bpsgos.2026.100725_bib32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S2215-0366(14)00092-3","article-title":"Placebo effects in psychiatry: Mediators and moderators","volume":"2","author":"Weimer","year":"2015","journal-title":"Lancet Psychiatry"}],"container-title":["Biological Psychiatry Global Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667174326000388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667174326000388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:41:23Z","timestamp":1783100483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667174326000388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2667174326000388"],"URL":"https:\/\/doi.org\/10.1016\/j.bpsgos.2026.100725","relation":{},"ISSN":["2667-1743"],"issn-type":[{"value":"2667-1743","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a Study","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry Global Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpsgos.2026.100725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 THE AUTHORS. Published by Elsevier Inc on behalf of the Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}],"article-number":"100725"}}